Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Lademann
Anne-Marie Lademann, Charlottenlund DK
| Patent application number | Description | Published |
|---|---|---|
| 20080234352 | Controlled release solid dispersions - A controlled release pharmaceutical composition for oral use comprising a solid dispersion of i) at least one therapeutically, prophylactically and/or diagnostically active substance, which at least partially is in an amorphous form, ii) a pharmaceutically acceptable polymer that has plasticizing properties, and iii) optionally a stabilizing agent, the at least one active substance having a limited water solubility, and the composition being designed to release the active substance with a substantially zero order release. The polymer is typically a poly ethylene glycol and/or polyethylene oxide having a molecular weight of at least about 20,000 in crystalline and/or amorphous form or a mixture of such polymers, and the active substance is typically carvedilol. The composition may comprise a coated matrix, the coating comprising a first cellulose derivative which is substantially insoluble in the aqueous medium, and at least one of a) a second cellulose derivative which is soluble or dispersible in water, b) a plasticizer, and c) a filler. | 09-25-2008 |
| 20080254122 | Polymer release system - A pharmaceutical composition for controlled release of an active substance, the composition being a matrix composition of: (a) a substantially water soluble or crystalline polymer, (b) an active substance, and optionally, (c) one or more pharmaceutically acceptable excipients having a water solubility of at least 1 mg/ml at ambient temperature. The matrix composition does not contain a water dispersible or water soluble surface active agent that has at least one domain, which is compatible with the polymer in the matrix composition, and which substantially eliminates water diffusion between the interface between the polymer crystals. | 10-16-2008 |
| 20080268057 | Controlled release carvedilol compositions - A controlled release pharmaceutical composition for oral use comprising carvedilol. The composition releases carvedilol after oral administration to a mammal, including a human, in such a manner that a prolonged residence of carvedilol is obtained in the circulatory system compared with the known compositions of carvedilol. Furthermore, a composition according to the present invention makes available to the body a suitable plasma concentration of one or both of the enantiomeric species, namely R(+) and/or S(−) carvedilol for obtaining the desired therapeutic effect. | 10-30-2008 |
| 20100166866 | MATRIX COMPOSITIONS FOR CONTROLLED DELIVERY OF DRUG SUBSTANCES - A novel matrix composition for pharmaceutical use. The matrix composition has been designed so that it is especially suitable in those situation where an improved bioavailability is desired and/or in those situation where a slightly or insoluble active substance is employed. Accordingly, a controlled release pharmaceutical composition for oral use is provided in the form of a coated matrix composition, the matrix composition comprising i) a mixture of a first and a second polymer that have plasticizing properties and which have melting points or melting intervals of a temperature of at the most 200° C., the first polymer being selected from the group consisting of polyethylene glycols and polyethylene oxides, and the second polymer being selected form block copolymer of ethylene oxide and propylene oxide including poly(ethylene-glycol-b-(DL-lactic acid-co-glycolic acid)-b-ethylene glycol (PEG-PLGA PEG), poly((DL-lactic acid-co-glycolic acid)-g-ethylene glycol) (PLGA-g-PEG), poloxamers and polyethylene oxide-polypropylene oxide (PEO-PPO), ii) a therapeutically, prophylactically and/or diagnostically active substance, the matrix composition being provided with a coating having at least one opening exposing at one surface of said matrix, wherein the active substance is released with a substantially zero order release. | 07-01-2010 |
Anne-Marie Lademann, Klampenborg DK
| Patent application number | Description | Published |
|---|---|---|
| 20100105717 | TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS - An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form. | 04-29-2010 |
| 20110275659 | Tacrolimus For Improved Treatment Of Transplant Patients - An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form. | 11-10-2011 |
Helmut Lademann, Hurth DE
| Patent application number | Description | Published |
|---|---|---|
| 20110240483 | METHOD FOR ENSURING AND MONITORING ELECTROLYZER SAFETY AND PERFORMANCES - There is described a method for ensuring and monitoring electrolyzer safety and performances in a manufacturing process which uses at least one electrolyzing cell containing at least one cathode and at least one anode separated by a membrane, comprising the step of: determining a safe single voltage operation range depending of the current and corresponding to the normally working electrolyzing cell; determining a reference voltage deviation depending on the time derivation of the current; measuring the voltage over time at the terminals of the electrolyzing cell; determining the measured voltage deviation by calculating the time derivative of the measured voltage; comparing the measured voltage to the safe single voltage operation range and the measured voltage deviation to the reference voltage deviation over time; stopping the manufacturing process when the measured voltage is outside the safe single voltage operation range or the difference between the measured voltage deviation and the reference voltage deviation is outside a predetermined range or a single voltage behavior is different than the average of a group of reference cells. | 10-06-2011 |
Jacob Bo Lademann, Copenhagen S DK
| Patent application number | Description | Published |
|---|---|---|
| 20120003741 | HEPATITIS C VIRUS EXPRESSING REPORTER TAGGED NS5A PROTEIN - The present inventors developed hepatitis C reporter viruses containing Core through NS2 of prototype isolates of all major HCV genotypes and the remaining genes of isolate JFH1, by insertion of reporter genes in domain III of HCV NS5A. The inventors have identified a deletion upstream of the inserted reporter gene sequence, which conferred favourable growth kinetics in Huh7.5 cells to these viruses. These reporter viruses can be used for high throughput analysis of drug and vaccine candidates as well as patient samples. Drugs could be evaluated for their potential to prevent infection or cure infected cells. The neutralizing capacity of antibodies induced by vaccine candidates could be evaluated in order to define successful vaccination strategies. Broadly neutralizing antibodies could be identified testing engineered antibodies and antibodies derived from serum of HCV infected individuals; thus this technique could contribute to the development of immunotherapy. The developed systems could aid individualized treatment of HCV infected: Patient isolates could be tested for resistance to drugs by introduction of genome regions involved in drug resistance in the developed constructs and subsequent treatment with the drug of interest. The present inventors also developed JFH1-based intergenotypic recombinants with genotype specific homotypic 5UTR, or heterotypic 5′UTR (either of genotype 1a (strain H77) or of genotype 3a (strain S52)). The present inventors additionally developed J6/JFH1 recombinants with the 5′UTR of genotypes 1-6. These recombinants with different 5UTRs are a useful to study the function of the 5′UTR in a genotype specific manner. | 01-05-2012 |
Jurgen Lademann, Berlin DE
| Patent application number | Description | Published |
|---|---|---|
| 20110054429 | Textile Composite Material for Decontaminating the Skin - An absorbent textile composite material for decontaminating the skin. The absorbent textile composite material comprises a flexible carrier layer and an active layer connected with the carrier layer. The active layer comprises a nanofiber nonwoven filled with a superabsorbent to absorb and retain noxious substances from the skin. The absorbent textile composite material is used in a method for decontaminating the skin from noxious substances without a washing and/or massage procedure. | 03-03-2011 |
| 20110172507 | Textile Composite Material Comprising Nanofiber Nonwoven - Among others, the present invention provides an absorbent textile composite material which comprises a flexible carrier layer and an active layer connected with the carrier layer, wherein the active layer comprises a nanofiber nonwoven optionally filled with a superabsorbent. | 07-14-2011 |